Medimaps markets AI-driven bone microarchitecture imaging technologies such as TBS Osteo and TBS Reveal, which assess ...

Theravance Biopharma is set to lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.  | Theravance Biopharma will lay off 50% of ...

Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate. | Disc Medicine is laying off a fifth of its workforce as the ...

Biohaven is powering ahead with its bold ambition to sharply reduce R&D spending—even as analysts warn the company will need to be even stricter with its expenditures. | Biohaven is powering ahead ...

Two new cancer cases have prompted Kyowa Kirin to shutter all clinical studies of its investigational anti-OX40 monoclonal antibody designed to treat inflammatory diseases. | Two new cancer cases have ...

RGX-121 was rejected in early February, with Regenxbio listing the primary reasons given by the FDA as concerns about the ability to properly define a patient population, the use of a natural history ...

The company’s brain technology platform taps software, sensors and telehealth across clinic and home settings in treatment areas including stroke, Parkinson’s disease and at-risk aging. Meanwhile, ...